)
Visual24 Oct 2025
The rise of Alphabet
Janux Therapeutics (JANX) investor relations material
Janux Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary7 Aug, 2025
Executive summary
Report covers the quarter ended June 30, 2025, for a clinical-stage biopharmaceutical company focused on immunotherapies for cancer and autoimmune diseases, with lead candidates JANX007 and JANX008 in Phase 1 trials and a broad preclinical pipeline.
R&D Day showcased progress in TRACTr, TRACIr, and ARM pipelines, emphasizing best-in-class potential for autoimmune diseases.
Enrollment is ongoing for JANX007 (prostate cancer) and JANX008 (multiple solid tumors), with data updates expected in H2 2025.
No product revenue has been generated; all revenue to date is from a collaboration with Merck, which concluded its research phase in August 2024.
Net losses continue to increase due to higher R&D and administrative expenses, with a significant cash position maintained through recent equity offerings.
Financial highlights
Net loss for Q2 2025 was $33.9 million, compared to $6.0 million in Q2 2024; net loss for the six months ended June 30, 2025, was $57.4 million, up from $20.7 million year-over-year.
Research and development expenses rose to $34.7 million in Q2 2025 (from $14.9 million) and $59.7 million for the six months (from $29.0 million), driven by increased preclinical and clinical activities.
General and administrative expenses increased to $10.5 million in Q2 2025 (from $7.8 million) and $20.3 million for the six months (from $15.2 million), mainly due to higher stock-based compensation and professional fees.
Cash, cash equivalents, and short-term investments totaled $996.8 million at June 30, 2025, down from $1.03 billion at year-end 2024.
Interest income rose to $11.3 million in Q2 2025 (from $7.9 million) and $22.6 million for the six months (from $13.3 million), reflecting higher cash and investment balances.
Outlook and guidance
Expenses and operating losses are expected to increase substantially as research and development activities expand.
Existing cash, cash equivalents, and short-term investments of $996.8 million as of June 30, 2025, are expected to fund operations for at least the next 12 months.
No product revenue is anticipated for several years; future funding will rely on equity, debt, or partnership arrangements.
Additional clinical data from JANX007 and JANX008 will be presented in the second half of 2025.
Multiple preclinical candidates are advancing toward clinical trials, including TROP2-TRACTr and CD19-ARM.
Detail Q2 2025 R&D expense increase drivers
Future milestones from Merck collaboration
CD19-ARM autoimmune program development strategy
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Janux Therapeutics earnings date
Q3 20254 Nov, 2025
Next Janux Therapeutics earnings date
Q3 20254 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer treatment. The company leverages its proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to create targeted therapies that activate the immune system specifically within the tumor microenvironment, minimizing systemic side effects. Janux Therapeutics is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage